Consider Cardiovascular Benefits When Choosing Metformin Add-ons

August 2016

Cardiovascular impact will be considered more when choosing drugs to add to metformin.

We're used to picking diabetes meds based on their A1C lowering, side effects, cost, etc. But now CV impact will also be important.

In fact, the SGLT2 inhibitor Jardiance (empagliflozin) is poised to become the first diabetes med approved for reducing CV death in patients with type 2 diabetes and CV disease. It prevents CV death in one in 45 patients over 3 years...and overall mortality in one in 39 patients.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote